Segmed Highlights Role in JPM2026 Discussion on AI and Real-World Evidence in Healthcare

Segmed has shared an update. The company announced its role as co-organizer of a JPM2026 side event in San Francisco hosted by Cromodata, focused on how artificial intelligence and real-world evidence (RWE) are transforming healthcare. Segmed’s CEO, David Gascoigne, will participate in a panel discussion on secure, anonymized data and the development of trusted data ecosystems to accelerate scientific discovery and real-world clinical impact.

For investors, this participation underscores Segmed’s strategic positioning within the growing market for healthcare data platforms and AI-driven evidence generation. Co-organizing an event alongside other industry leaders at a high-profile conference such as JPM suggests active engagement with potential partners, customers, and investors, which could support future business development and deal flow. The emphasis on secure, anonymized data and RWE aligns with regulatory and payer trends favoring data-driven decision-making, potentially enhancing Segmed’s relevance to biopharma, medtech, and healthcare providers seeking compliant data solutions. While the post does not disclose financial metrics, contracts, or product launches, it indicates continued efforts to build thought leadership and network in a segment where scale, data access, and trusted infrastructure are key competitive differentiators. Over time, successful execution of this strategy could improve Segmed’s commercial pipeline and strengthen its position within the healthcare data and AI ecosystem.